AVE STOCK CLIMBS 13% IN JANUARY ON COMPANY PRODUCT APPROVALS, STRONG WORLDWIDE CORONARY STENT MARKET OUTLOOK; O-T-C INDEX COMPOSITE UP 3.2%
This article was originally published in The Gray Sheet
Arterial Vascular Engineering stock's January debut on "The Gray Sheet" Index coincided with a solid 8-1/2 point (13.1%) run-up during the month to 73-1/2. Investor enthusiasm for the issue, roused by the Dec. 23 approval of the company's Micro Stent II and GFX coronary stent systems, was heightened further by Wall Street predictions of "explosive" stent market growth in 1998.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.